1 / 2

KRAS

Spectre des mutations recherchées chez les patients chimioréfractaires et traités par panitumumab en monothérapie. KRAS. EXON 1. EXON 2. EXON 3. EXON 4. EXON 1. EXON 2. EXON 3. EXON 4. NRAS. Survie globale des patients KRAS , NRAS-WT en fonction du traitement.

mariko-white
Download Presentation

KRAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Spectre des mutations recherchées chez les patients chimioréfractaires et traités par panitumumab en monothérapie KRAS EXON 1 EXON 2 EXON 3 EXON 4 EXON 1 EXON 2 EXON 3 EXON 4 NRAS Chicago 2013 – D'après Patterson SD et al., abstract 3617, actualisé

  2. Survie globale des patients KRAS, NRAS-WT en fonction du traitement HR = 0,78 ; IC95 : 0,62-0,99 ; p = 0,043 FOLFOX4 Panitumumab + FOLFOX4 Chicago 2013 – D'après Oliner KS et al., abstract 3511, actualisé

More Related